Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Respirol Case Rep ; 8(3): e00540, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32148839

ABSTRACT

Diagnosis in cases with pulmonary lymphangitic carcinomatosis as a primary manifestation is difficult due to unawareness of the cancer. An 81-year-old man was admitted due to a one-week history of dyspnoea and haemoptysis. Chest computed tomography showed diffuse bilateral ground-grass opacity and partial consolidation. We suspected diffuse alveolar haemorrhage. High-dose methylprednisolone and cyclophosphamide did not improve his condition and he died from respiratory failure. Autopsy revealed pulmonary lymphangitic carcinomatosis of whole lungs and primary gallbladder cancer. We should consider pulmonary lymphangitic carcinomatosis in the differential diagnosis of patients with haemoptysis and diffuse lung opacity of unknown origin.

2.
Head Neck ; 37(5): E63-5, 2015 May.
Article in English | MEDLINE | ID: mdl-25270910

ABSTRACT

BACKGROUND: The purpose of this study was to report the treatment outcome of a patient with nasopharyngeal small cell carcinoma. METHODS: The patient received concurrent chemoradiotherapy (CRT). Chemotherapy consisted of 4 cycles of cisplatin and etoposide. Accelerated hyperfractionated radiotherapy (RT) was performed with a dose of 45 Gy in 30 fractions over 3 weeks for the nasopharynx and upper neck region, whereas conventional fractionated RT was performed with a dose of 50 Gy in 25 fractions over 5 weeks for the lower neck region. RESULTS: Complete response was achieved 1 month after the completion of CRT. Prophylactic cranial irradiation was not performed. Isolated brain metastasis was diagnosed 18 months after the completion of CRT. Finally, the patient died because of the brain and cord metastases 32 months after the completion of CRT. CONCLUSION: The administration of prophylactic cranial irradiation may be considered for nasopharyngeal small cell carcinoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Small Cell/therapy , Nasopharyngeal Neoplasms/therapy , Carcinoma, Small Cell/pathology , Chemoradiotherapy , Cisplatin/administration & dosage , Dose Fractionation, Radiation , Etoposide/administration & dosage , Follow-Up Studies , Humans , Male , Middle Aged , Nasopharyngeal Neoplasms/pathology , Neoplasm Invasiveness/pathology , Neoplasm Staging , Risk Assessment , Treatment Outcome
3.
Acta Med Okayama ; 65(1): 27-32, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21339793

ABSTRACT

We performed a retrospective study examining the prevalence and subtypes of pulmonary emphysema (PE) identified by computed tomography (CT) in females. We reviewed the records of 1,687 female subjects who had undergone CT. They were divided into the following 2 age groups:group A (<50 years) and group B (≥50 years). PE was diagnosed by the presence of low-attenuation areas using visual assessment (grades 0-3) on CT images. Two subtypes of PE were observed:centrilobular emphysema (CLE) and paraseptal emphysema (PSE). PE was divided into the following 3 categories:I (CLE or CLE-predominant);II (CLE and PSE of equal extent);and III (PSE or PSE-predominant). PE was found in 64 of 274 smokers (23.3%) and 54 of 1,413 non-smokers (3.8%). In smoking subjects, when grades 1 and 2 were grouped together as mild PE, the mean age for CT grade 3 (severe PE) was significantly higher than that for mild PE. In group A, category III predominated, whereas category I was more prevalent in group B, in both smoking and non-smoking subjects. A high incidence of PE was found in smoking subjects as compared with non-smoking subjects. PSE predominated in younger subjects, whereas CLE predominated in older subjects.


Subject(s)
Pulmonary Emphysema , Severity of Illness Index , Smoking/epidemiology , Tomography, X-Ray Computed , Adult , Aged , Aged, 80 and over , Female , Humans , Incidence , Middle Aged , Prevalence , Pulmonary Emphysema/classification , Pulmonary Emphysema/diagnostic imaging , Pulmonary Emphysema/epidemiology , Retrospective Studies
4.
Int J Radiat Oncol Biol Phys ; 77(2): 337-43, 2010 Jun 01.
Article in English | MEDLINE | ID: mdl-19775827

ABSTRACT

PURPOSE: To evaluate the incidental irradiation dose to elective nodal regions in the treatment of advanced non-small-cell lung cancer with involved-field radiation therapy (IF-RT) and the pattern of elective nodal failure (ENF). METHODS AND MATERIALS: Fifty patients with advanced non-small-cell lung cancer, who received IF-RT at Kagawa University were enrolled. To evaluate the dose of incidental irradiation, we delineated nodal regions with a Japanese map and the American Thoracic Society map (levels 1-11) in each patient retrospectively and calculated the dose parameters such as mean dose, D95, and V95 (40 Gy as the prescribed dose of elective nodal irradiation). RESULTS: Using the Japanese map, the median mean dose was more than 40 Gy in most of the nodal regions, except at levels 1, 3, and 7. In particular, each dosimetric parameter of level 1 was significantly lower than those at other levels, and each dosimetric parameter of levels 10 to 11 ipsilateral (11I) was significantly higher than those in other nodal regions. Using the American Thoracic Society map, basically, the results were similar to those of the Japanese map. ENF was observed in 4 patients (8%), five nodal regions, and no mean dose to the nodal region exceeded 40 Gy. On the Japanese map, each parameter of these five nodal region was significantly lower than those of the other nodal regions. CONCLUSIONS: These results show that a high dose of incidental irradiation may contribute to the low incidence of ENF in patients who have received IF-RT.


Subject(s)
Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/radiotherapy , Lymphatic Irradiation/methods , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/administration & dosage , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/secondary , Cisplatin/administration & dosage , Docetaxel , Female , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lymphatic Metastasis , Male , Middle Aged , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Taxoids/administration & dosage
5.
Nucl Med Commun ; 30(1): 25-9, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19306511

ABSTRACT

OBJECTIVE: To evaluate whether 2-deoxy-2-18F-fluoro-D-glucose (FDG) positron emission tomography (PET) is more useful in differentiating malignant from benign pleural lesions, and whether delayed FDG PET imaging can improve the diagnostic performance in patients with suspicion of malignant pleural mesothelioma (MPM). METHODS: Thirty-three patients who were suspected of having MPM were examined with FDG PET. PET imaging (whole body) was performed at 60 min (early) post-FDG injection and repeated at 120 min (delayed) after injection only in the thoracic region. We evaluated the FDG uptake visually and semiquantitatively. The semiquantitative analysis using the standardized uptake value (SUV) was determined for both early and delayed images (SUVearly and SUVdelayed, respectively). RESULTS: The final diagnosis was MPM in 17 patients and benign pleural disease in 16 patients. The sensitivity, specificity, and accuracy to detect MPM on both early and delayed PET were all 88%. The mean value of SUVdelayed in MPM was significantly higher than that of SUVearly (P < 0.001). The mean values of SUVearly and SUVdelayed in MPM were significantly higher than the corresponding values in benign pleural disease (P < 0.01, respectively). CONCLUSION: FDG PET seems to be a useful imaging modality for differential diagnosis of MPM. In addition, the diagnostic performance on delayed PET was the same as that on early PET, although SUVdelayed was significantly higher than SUVearly in patients with MPM.


Subject(s)
Fluorodeoxyglucose F18 , Mesothelioma/diagnostic imaging , Mesothelioma/pathology , Positron-Emission Tomography/methods , Aged , Aged, 80 and over , Diagnosis, Differential , Female , Fluorodeoxyglucose F18/metabolism , Humans , Male , Mesothelioma/metabolism , Middle Aged , Sensitivity and Specificity , Time Factors
6.
Magn Reson Med Sci ; 6(4): 225-9, 2007.
Article in English | MEDLINE | ID: mdl-18239359

ABSTRACT

PURPOSE: We assessed the feasibility of utilizing three-dimensional (3D) phase sensitive inversion recovery (IR) images for preoperatively determining deep brain stimulator position. METHODS: We measured geometric distortion with a grid phantom and evaluated images of 3 volunteers to determine optimum imaging parameters for 3D phase sensitive IR. RESULTS: Geometric distortion measured less than 1.0%. Respective inversion and recovery times, which provided high T(1) contrast between the subthalamic nucleus and adjacent tissue, were 200 and 4000 ms. In studies of 3 volunteers and 2 patients, the subthalamic nucleus was clearly depicted in 3D phase sensitive IR images. The measured coordinates of the subthalamic nucleus agreed well with those calculated by conventional estimation from midpoint of the anterior and posterior commissure. CONCLUSION: Three-dimensional phase sensitive inversion recovery was useful in visualizing the subthalamic nucleus for effective deep brain stimulation.


Subject(s)
Brain Mapping/methods , Deep Brain Stimulation , Imaging, Three-Dimensional , Magnetic Resonance Imaging/methods , Subthalamic Nucleus/anatomy & histology , Subthalamic Nucleus/surgery , Adult , Female , Humans , Male , Parkinson Disease/pathology , Parkinson Disease/therapy , Phantoms, Imaging
7.
Gan To Kagaku Ryoho ; 32(9): 1279-82, 2005 Sep.
Article in Japanese | MEDLINE | ID: mdl-16184924

ABSTRACT

The clinical efficacy and safety of hyperfractionated radiotherapy with concurrent chemotherapy were studied retrospectively in patients with primary advanced esophageal cancer. The subjects were 31 patients who were treated with hyperfractionated radiotherapy and concurrent chemotherapy in our institution between 1990 and 2001. The chemoradiotherapy consisted of cisplatin 70-80 mg/m2 on day one, and continuous infusion of 5-fluorouracil 700-800 mg/m2/24 hours on days 1 to 3, with concurrent hyperfractionated radiotherapy (57.6-72 Gy). Complete remission (CR) was observed in 17 cases, and partial response in 13 cases (response rate: 96. 7%). Three-year survival rate and 5-year survival rate were 35.5% and 26.3%, respectively. Grade 3/4 hematological toxicities included leukocytes in 7 patients (22.6%), hemoglobin in 6 patients (19.4%), and platelets in 4 patients (12.9%). Grade 3 dysphagia-esophageal related to radiation was observed in 3 patients (9.7%). Late toxicities occurred with the following incidences: hypothyroidism in 2 patients, benign esophageal strictures in 2 patients, pericardial effusion in 8 patients, and pleural effusion in 8 patients. The results suggest that combined chemotherapy and hyperfractionated radiotherapy is an effective and well-tolerated regimen.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dose Fractionation, Radiation , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/radiotherapy , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cisplatin/administration & dosage , Combined Modality Therapy , Deglutition Disorders/etiology , Drug Administration Schedule , Esophageal Neoplasms/mortality , Female , Fluorouracil/administration & dosage , Humans , Hypothyroidism/etiology , Infusions, Intravenous , Leukopenia/chemically induced , Male , Middle Aged , Remission Induction , Retrospective Studies , Survival Rate
8.
Ann Nucl Med ; 19(8): 725-8, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16445000

ABSTRACT

Pyothorax-associated lymphoma (PAL) is a non-Hodgkin's lymphoma developing in the pleural cavity after a long-standing history of chronic pyothorax (CP). F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging is a useful modality for determination of disease extent of various malignant tumors, including malignant lymphoma, but there have been no reports describing the usefulness of FDG-PET imaging in PAL. Here we report a case of PAL that relapsed after chemotherapy and was successfully treated by radiotherapy. FDG-PET imaging revealed that the tumor was localized to a soft-tissue attenuation mass behind the CP cavity in the right thorax, but did not infiltrate the CP cavity. A total dose of 40 Gy was administered to the area that included the PET-positive lesion, instead of including the entire CP cavity in the radiation field. Although computed tomography (CT) showed a residual mass, no FDG uptake was indicated by FDG-PET imaging performed just after the end of radiotherapy, and additional irradiation was not performed. No sign of relapse was found by FDG-PET imaging 3 months later. FDG-PET imaging was useful for both the planning of radiotherapy and assessing the treatment response of PAL.


Subject(s)
Empyema, Pleural/diagnostic imaging , Fluorodeoxyglucose F18 , Lymphoma, Non-Hodgkin/diagnostic imaging , Lymphoma, Non-Hodgkin/radiotherapy , Pleural Neoplasms/diagnostic imaging , Pleural Neoplasms/radiotherapy , Radiotherapy Planning, Computer-Assisted/methods , Aged , Empyema, Pleural/complications , Humans , Lymphoma, Non-Hodgkin/etiology , Pleural Neoplasms/etiology , Positron-Emission Tomography/methods , Prognosis , Radiopharmaceuticals , Radiotherapy, Computer-Assisted/methods , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...